One of the scientists behind the Oxford/AstraZeneca Covid-19 vaccine has defended a decision to make profits on new supply deals, as the partnership announced that more than 2bn doses had been delivered.
Sandy Douglas, a research group leader at Oxford, said in an interview that it was “a distraction for people to latch on to the pricing”, and that this was “losing sight of what’s really important”.
Oxford university said that it had reached the 2bn milestone by using a strategy that involved “feeding” certain nutrients to vaccine-making cells, allowing more to be made in each batch.
您已阅读23%（589字），剩余77%（1941字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。